EPIRUS Biopharma (EPRS) Misses Q4 EPS by 7c

EPIRUS Biopharma (NASDAQ: EPRS) reported Q4 EPS of ($0.63), $0.07 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $285 thousand versus the consensus estimate of $230 thousand.

Cash and cash equivalents and marketable securities, collectively "cash," totaled $31.5 million at December 31, 2015. The Company is in the process of evaluating various financing alternatives for operations, by raising additional capital through equity or debt financings or entering into collaboration agreements.

For earnings history and earnings-related data on EPIRUS Biopharma (EPRS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M